Oncology Pipeline
For Boehringer Ingelheim, Cancer Care is personal - today and for generations
We have a clear aspiration – to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. Our generational commitment to driving scientific innovation is reflected by our robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches. We are taking a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research.
Highlights
![MDM2-p53 antagonist: NCT05512377 (Brightline-2, 1403.11 MDM2-p53 antagonist: NCT05512377 (Brightline-2, 1403.11](/inoncology/sites/default/files/2024-05/Brightline-4-study-design.png)
Clinical trial: Brightline-4
Phase III trial investigating the use of brigimadlin in the treatment of dedifferentiated liposarcoma
![BI 1810631: NCT04886804 (Beamion LUNG-1, 1479.1) BI 1810631: NCT04886804 (Beamion LUNG-1, 1479.1)](/inoncology/sites/default/files/2024-05/Beamion-LUNG-2-study-design.png)
Clinical trial: Beamion LUNG-2
Phase III trial of zongertinib in the treatment of NSCLC with documented HER2 mutation
![Phase II trial of our DLL3/CD3 T-cell engager (BI 764532) in the treatment of SCLC and Phase II trial of our DLL3/CD3 T-cell engager (BI 764532) in the treatment of SCLC and](/inoncology/sites/default/files/2024-05/DAREON-5-1438-0005-study-design.png)
Clinical trial: Dareon-5
Phase II trial of our DLL3/CD3 T-cell engager (BI 764532) in the treatment of SCLC and other NECs